| Literature DB >> 30386173 |
Ludivine Renaud1, Willian A da Silveira1, William B Glen1, Edward S Hazard1, Gary Hardiman1.
Abstract
BACKGROUND: Cellular homeostasis is regulated by the intricate interplay between a plethora of signaling pathways and "energetic sensors" in organs. In order to maintain energy balance, induction or repression of metabolic pathways must be regulated and act in concert with the energetic demands of the cell at a given point in time. A new class of small noncoding RNAs, the microRNAs (miRNAs), has added yet further complexity to the control of metabolic homeostasis.Entities:
Keywords: Bioinformatics; Homeostasis; MicroRNAs; Non-coding RNAs; Systems level analysis; Zebrafish; mRNAs
Year: 2018 PMID: 30386173 PMCID: PMC6194436 DOI: 10.2174/1389202919666180503124522
Source DB: PubMed Journal: Curr Genomics ISSN: 1389-2029 Impact factor: 2.236
Fig. (4)Scenarios to analyze networks of miRNAs and their target genes. A) In the 1st scenario, we analyzed the impact of the 9 miRNAs uniquely expressed in the liver onto the liver transcriptome (5988 genes, blue box) and the impact of the 18 miRNAs uniquely expressed in the gut onto the gut transcriptome (5817 genes, red box). B) In the 2nd scenario, we created a network between the 215 miRNAs commonly expressed in both liver and gut tissues and the 1,550 genes uniquely expressed in the liver (green box) as well as another network between the 215 miRNAs commonly expressed and the 1,379 genes uniquely expressed in the gut (purple box). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this paper.)
Impact on the liver unique transcriptome of the 215 miRNAs commonly expressed in the liver and the gut (2nd scenario). Only the top 20 miRNAs are shown here based on the number of predicted genes found.
|
|
|
|
|
|---|---|---|---|
| dre-miR-2184 | 290 | 28.7 | 18.7 |
| dre-miR-23b | 284 | 28.1 | 18.3 |
| dre-miR-23a-3p | 284 | 28.1 | 18.3 |
| dre-miR-101a | 254 | 25.2 | 16.4 |
| dre-miR-101b | 253 | 25.1 | 16.3 |
| dre-miR-141-3p | 246 | 24.4 | 15.9 |
| dre-miR-200a-3p | 246 | 24.4 | 15.9 |
| dre-miR-181c-5p | 235 | 23.3 | 15.2 |
| dre-miR-181b-5p | 235 | 23.3 | 15.2 |
| dre-miR-181a-5p | 234 | 23.2 | 15.1 |
| dre-miR-30e-5p | 222 | 22.0 | 14.3 |
| dre-miR-30c-5p | 221 | 21.9 | 14.2 |
| dre-miR-30b | 220 | 21.8 | 14.2 |
| dre-miR-30a-5p | 217 | 21.5 | 14.0 |
| dre-miR-30d | 216 | 21.4 | 13.9 |
| dre-miR-19b-3p | 215 | 21.3 | 13.9 |
| dre-miR-19d-3p | 215 | 21.3 | 13.9 |
| dre-miR-19a-3p | 215 | 21.3 | 13.9 |
| dre-miR-19c-3p | 215 | 21.3 | 13.9 |
| dre-miR-725-3p | 209 | 20.7 | 13.5 |
Impact on the gut unique transcriptome of the 215 miRNAs commonly expressed in the liver and the gut (2nd scenario). Only the top 20 miRNAs are shown here based on the number of predicted genes found.
|
|
|
|
|
|---|---|---|---|
| dre-miR-2184 | 329 | 34.6 | 23.8 |
| dre-miR-101a | 323 | 34.0 | 23.4 |
| dre-miR-101b | 322 | 33.9 | 23.3 |
| dre-miR-181c-5p | 319 | 33.6 | 23.1 |
| dre-miR-181a-5p | 319 | 33.6 | 23.1 |
| dre-miR-181b-5p | 319 | 33.6 | 23.1 |
| dre-miR-23a-3p | 302 | 31.8 | 21.9 |
| dre-miR-23b | 300 | 31.6 | 21.7 |
| dre-miR-19d-3p | 256 | 26.9 | 18.6 |
| dre-miR-19c-3p | 256 | 26.9 | 18.6 |
| dre-miR-19b-3p | 256 | 26.9 | 18.6 |
| dre-miR-19a-3p | 256 | 26.9 | 18.6 |
| dre-miR-30e-5p | 246 | 25.9 | 17.8 |
| dre-miR-30b | 243 | 25.6 | 17.6 |
| dre-miR-30c-5p | 243 | 25.6 | 17.6 |
| dre-miR-725-3p | 242 | 25.5 | 17.5 |
| dre-miR-93 | 240 | 25.3 | 17.4 |
| dre-miR-17a-5p | 239 | 25.2 | 17.3 |
| dre-miR-30d | 238 | 25.1 | 17.2 |
| dre-miR-20b-5p | 238 | 25.1 | 17.2 |
iPathwayGuide - Biological Pathways. Only the top 20 pathways are shown here based on q-value.
|
|
|
|---|---|
| Ribosome | 1.0E-24 |
| Metabolic pathways | 3.2E-21 |
| Oxidative phosphorylation | 1.3E-10 |
| Carbon metabolism | 3.7E-07 |
| Glycolysis/Gluconeogenesis | 2.3E-06 |
| Systemic lupus erythematosus | 3.5E-05 |
| Fatty acid degradation | 7.2E-05 |
| Tryptophan metabolism | 1.1E-04 |
| Complement and coagulation cascades | 1.2E-04 |
| Parkinson’s disease | 1.8E-04 |
| Alzheimer’s disease | 2.3E-04 |
| Non-Alcoholic Fatty Liver Disease (NAFLD) | 2.7E-04 |
| Huntington’s disease | 2.7E-04 |
| 1.5E-03 | |
| Vitamin digestion and absorption | 2.0E-03 |
| Pyruvate metabolism | 2.2E-03 |
| Protein digestion and absorption | 2.2E-03 |
| Glycine, serine and threonine metabolism | 2.4E-03 |
| Lysine degradation | 2.4E-03 |
| Biosynthesis of amino acids | 3.2E-03 |